Ignite Creation Date:
2024-05-06 @ 4:13 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04919616
Status:
NOT_YET_RECRUITING
Last Update Posted:
2021-06-09
First Post:
2021-05-11
Brief Title:
An Exploratory Clinical Study of TILs in the Treatment of Recurrent Refractory Non-small Cell Lung Cancer NSCLC
Sponsor:
Shanghai OriginCell Therapeutics Co Ltd
Organization:
Shanghai OriginCell Therapeutics Co Ltd
Study Overview
Official Title:
An Exploratory Clinical Study of Autologous Tumor Infiltrating Lymphocytes TILs in the Treatment of Recurrent and Refractory Non-small Cell Lung Cancer NSCLC
Status:
NOT_YET_RECRUITING
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is an open single-arm dose-escalating phase I exploratory clinical trial to observe the safety tolerability and preliminary efficacy of different doses of TILs in the treatment of relapsed and refractory NSCLCNon-small cell lung cancer
The study includes 7 stages ① screening period ② tissue collection ③ TILs cell production and preparation ④ lymphocyte depletion pretreatment ⑤ TILs cell infusion ⑥ safety and efficacy evaluation ⑦ follow-up
The study includes 7 stages ① screening period ② tissue collection ③ TILs cell production and preparation ④ lymphocyte depletion pretreatment ⑤ TILs cell infusion ⑥ safety and efficacy evaluation ⑦ follow-up
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None